Research & DevelopmentGermany to Provide 100,000 Mpox Vaccine Doses to Combat...

Germany to Provide 100,000 Mpox Vaccine Doses to Combat Outbreak in Africa

-

Germany has provided 100,000 doses of the Mpox vaccine from its armed forces to help combat the ongoing outbreak in Africa, a government spokesperson said.
This contribution is expected to bring swift relief to the continent and support the countries battling the virus. In addition to the vaccine donation, Germany will offer the WHO flexible human resources and financial support through various arrangements in the fight against Mpox. The German government will also assist African nations through the GAVI vaccine alliance, as part of its partnership with the continent.

Germany has approximately 117,000 doses of the Jynneos vaccine in its military supply, which were purchased in 2022. Some of these doses will be reserved for the protection of officers traveling to different stations, as confirmed by a defense ministry spokesperson on Monday.
The spokesperson also indicated that any further decisions regarding restocking vaccines would require additional discussions.
Mpox has been declared a global public health emergency by the WHO, particularly after an outbreak was reported in the Democratic Republic of Congo and subsequently spread to neighboring countries. The new variant of the virus, specifically Clade Ib, is of particular concern to experts due to its rapid propagation.
The German government is also seeking the quickest way to deliver the vaccines to the affected regions, particularly the Democratic Republic of Congo, Burundi, and other East African nations, according to a foreign ministry official.

Life Sciences Voice Logo mobile
+ posts

Latest news

Top 10 Pharma News Websites You Should Follow in 2026

Executive Summary In 2026, pharma and biotech are evolving at unprecedented speed. AI-driven drug discovery, digital transformation, personalized medicine, and...

How Are Life Sciences Companies Raising Capital in 2026?

Executive Summary In 2026, raising capital in life sciences is no longer about access—it is about proof. The traditional reliance...

Kailera Details Nasdaq IPO Plans to Raise Up to $528.5 Million for Obesity Drug Development

Kailera Therapeutics has provided additional details regarding its planned initial public offering, aiming to raise up to $528.5 million...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you